Previous 10 | Next 10 |
home / stock / nvs / nvs articles
MacroGenics Inc (NASDAQ:MGNX) released interim data from the TAMARACK Phase 2 study of vobramitamab duocarmazine (vobra duo). TAMARA...
Researchers at Alphabet Inc’s (NASDAQ:GOOG) (NASDAQ:GOOGL) Google DeepMind have developed AlphaFold 3, an new artificial intelligence (...
The Federal Trade Commission (FTC) is intensifying its efforts to challenge numerous pharmaceutical patent listings, aiming to facilitate...
Corporate earnings came to the market’s rescue in the past week, helping to overcome rate fears. As we look ahead to the unfolding week, it r...
GSK Plc (NYSE:GSK) has reportedly taken legal action against Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) in a...
Tuesday, Novartis AG (NYSE:NVS) received FDA approval for its Lutathera (lutetium Lu 177 dotatate / INN: lu...
Shares of Swiss pharma giant Novartis AG (NYSE:NVS) after the company raised its full-year guidance following better-than-expected first-quarter...
The mood on Wall Street turned tentative on Tuesday as investors awaited earnings reports from the “Magnificent 7,” companies that fuel...
The mood on Wall Street turned tentative on Tuesday as investors awaited earnings reports from the “Magnificent 7,” companies that fuel...
News, Short Squeeze, Breakout and More Instantly...
2024-07-12 13:15:04 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for NVS on July 12, 2024 11:58AM ET. The previous analyst recommendation was Equal-Weight. NVS was trading at $111.855 at issue of the analyst recommendation. The overall analyst consensus :...
2024-07-09 01:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...